Abstract P2-01-24: Immune activation of tumor cells and microenvironment as assessed by PD-L1 expression and interferon gamma signaling predict long term disease-free and overall survival: Results of the prospective randomized neoadjuvant ABCSG 34 trial
Ulrike Heber(Comprehensive Cancer Center Vienna), Zsuzsanna Bagó-Horváth(Comprehensive Cancer Center Vienna), Michael Gnant(Austrian Breast & Colorectal Cancer Study Group), Ruth Helfgott, Martin Filipits(University of Vienna), Daniel Egle, Rupert Bartsch(Universitätszahnklinik Wien), Sigurd Lax(Graz University Hospital), Margaretha Rudas(Comprehensive Cancer Center Vienna), Cornelia Hauser‐Kronberger(Paracelsus Medical University), Gabriel Rinnerthaler(Medical University of Graz), Richard Greil, Georg Pfeiler, Elisabeth Müller‐Holzner(Medical University of Graz), Christian F. Singer(Medical University of Vienna), Dominik Hlauschek(Austrian Breast & Colorectal Cancer Study Group)
Cited by 0
Related Papers
Breast cancer
|Nature Reviews Disease Primers|2019|2.9k
Breast cancer
|The Lancet|2016|2.3k
Tailoring therapies—improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015
|Annals of Oncology|2015|1.8k
ESMO-ESGO-ESTRO Consensus Conference on Endometrial Cancer: diagnosis, treatment and follow-up
|Annals of Oncology|2015|1.4k